XENTRIA Trademark
XENTRIA is a USPTO trademark filed by Xentria, Inc.. Status: Pending.
Trademark Facts
| Mark | XENTRIA |
|---|---|
| Serial Number | 99007883 |
| Status | Pending |
| Filing Date | 2025-01-17 |
| Mark Type | Word |
| Nice Classes | 005 (Pharmaceuticals) |
| Owner | Xentria, Inc. |
| Attorney of Record | Eric R. Moran |
| Prosecution Events | 15 |
| Latest Event | GNFN on 2026-03-03 |
Goods & Services
house mark for a full line of biologic, biosimilar, and pharmaceutical preparations; house mark for a full line of biologics; house mark for a full line of biosimilars; house mark for a full line of pharmaceuticals; house mark for a full line of biologic, biosimilar, and pharmaceutical products; biologic, biosimilar, and pharmaceutical preparations for the treatment of bone disease; biologic, biosimilar, and pharmaceutical preparations for use in the treatment of oncological and metabolic diseases and disorders, and complications associated therewith; biologic, biosimilar, and pharmaceutical preparations for the treatment of diabetes; biologic, biosimilar, and pharmaceutical preparations for treatment and prevention of autoimmune diseases and autoimmune disorders; biologic, biosimilar, and pharmaceutical oncology preparations; anti-inflammatories; biologic, biosimilar, and pharmaceutical preparations for the treatment of immune system related diseases and disorders; biologic, biosimilar, and pharmaceutical preparations for use in dermatology; biologic, biosimilar, and pharmaceutical preparations for use in rheumatology; biologic, biosimilar, and pharmaceutical preparations, namely, anti-tumor necrosis factor alpha (TNFa) receptor monoclonal antibody for the treatment of disease influenced by TNFa production; biologic, biosimilar, and pharmaceutical preparations, namely, biopharmaceuticals based on human monoclonal antibodies for the treatment of immune and inflammatory diseases and disorders